Urinary Proteome Differences in Patients with Type 2 Diabetes Pre and Post Liraglutide Treatment

Urinary Proteome Differences in Patients with Type 2 Diabetes Pre and Post Liraglutide Treatment

Diabetes mellitus is a chronic multisystem disease with a high global prevalence. The glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide is known to lower glucose levels and reduce weight. However, the mechanisms underlying the benefits of liraglutide treatment in patients with type 2 diab...

Full description

Bibliographic Details
Main Authors:	Mohamed Rafiullah, Hicham Benabdelkamel, Afshan Masood, Aishah A. Ekhzaimy, Mohthash Musambil, Salini Scaria Joy, Assim A. Alfadda
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Series:	Current Issues in Molecular Biology
Subjects:	GLP-1 receptors agonist liraglutide metallothionein-2 proteomics type 2 diabetes mellitus zinc-alpha-2-glycoprotein
Online Access:	https://www.mdpi.com/1467-3045/45/2/92

Similar Items

High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination
by: Marvin Wei Jie Chua
Published: (2021-12-01)

Fabrication and Evaluation of a pH-Responsive Nanocomposite-Based Colonic Delivery System for Improving the Oral Efficacy of Liraglutide
by: Song JG, et al.
Published: (2023-07-01)

Proteomic profiling of thyroid tissue in patients with obesity and benign diffuse goiter
by: Hicham Benabdelkamel, et al.
Published: (2022-07-01)

Effects of liraglutide on obesity-associated functional hypogonadism in men
by: M Jensterle, et al.
Published: (2019-02-01)

The Discovery and Development of Liraglutide and Semaglutide
by: Lotte Bjerre Knudsen, et al.
Published: (2019-04-01)

Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
by: J. Jendle, et al.
Published: (2021-12-01)

Growth differentiation factor‐15, treatment with liraglutide, and clinical outcomes among patients with heart failure
by: Abhinav Sharma, et al.
Published: (2021-08-01)

Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs
by: Åke Sjöholm
Published: (2010-03-01)

Efficacy and safety of liraglutide in Indian adolescents with obesity
by: I. S. Kochar, et al.
Published: (2019-06-01)

Liraglutide Activates Type 2 Deiodinase and Enhances β3-Adrenergic-Induced Thermogenesis in Mouse Adipose Tissue
by: Fernanda C. B. Oliveira, et al.
Published: (2022-01-01)

A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
by: Mariana Cornelia Tilinca, et al.
Published: (2021-06-01)

Liraglutide for the treatment of obesity
by: Elmien Bronkhorst, et al.
Published: (2016-05-01)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
by: Alexander Sergeevich Ametov, et al.
Published: (2011-12-01)

Continuation of Liraglutide during Fasting is not Associated with Hypoglycaemia
by: Rosalie Koot, et al.
Published: (2017-10-01)

Clinical Impact of Liraglutide as a Treatment of Obesity
by: Alruwaili H, et al.
Published: (2021-03-01)

Obezitenin Medikal Tedavisinde Liraglutide Etkinliğinin Araştırılması
by: Murat Kose, et al.
Published: (2023-09-01)

Proteomics Profiling of the Urine of Patients with Hyperthyroidism after Anti-Thyroid Treatment
by: Hicham Benabdelkamel, et al.
Published: (2021-04-01)

Plasma-Based Proteomics Profiling of Patients with Hyperthyroidism after Antithyroid Treatment
by: Afshan Masood, et al.
Published: (2020-06-01)

Proteomic Analysis of Endometrial Cancer Tissues from Patients with Type 2 Diabetes Mellitus
by: Muhammad Mujammami, et al.
Published: (2022-03-01)

Complex vasoactivity of liraglutide. Contribution of three gasotransmitters
by: Eszter Sélley, et al.
Published: (2015-05-01)

Editorial: Incretin agonists in the treatment of obesity
by: Xiaodong Sun, et al.
Published: (2023-08-01)

Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies
by: Guizhen Chang, et al.
Published: (2022-04-01)

Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease
by: Ying Liu, et al.
Published: (2017-12-01)

One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial
by: Louise Vedtofte, et al.
Published: (2020-10-01)

GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease
by: Kallirhoe Kalinderi, et al.
Published: (2024-03-01)

Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
by: Maria Mirabelli, et al.
Published: (2021-03-01)

Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype
by: Toomas Jagomäe, et al.
Published: (2021-11-01)

The Neuroprotective Effect of Liraglutide is Mediated by Glucagon-Like Peptide 1 Receptor-Mediated Activation of cAMP/PKA/CREB Pathway
by: Yi Bao, et al.
Published: (2015-07-01)

Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials
by: Xu Zhao, et al.
Published: (2019-01-01)

Clinical and Genetic Predictors of Glycemic Control and Weight Loss Response to Liraglutide in Patients with Type 2 Diabetes
by: Artemis Kyriakidou, et al.
Published: (2022-03-01)

Proteomic Profiling Identifies Distinct Regulation of Proteins in Obese Diabetic Patients Treated with Metformin
by: Awad Alshahrani, et al.
Published: (2023-09-01)

Clinical experience with Liraglutide in 196 patients with type 2 diabetes from a tertiary care center in India
by: Parjeet Kaur, et al.
Published: (2014-01-01)

Case Report: Off-Label Liraglutide Use in Children With Wolfram Syndrome Type 1: Extensive Characterization of Four Patients
by: Giulio Frontino, et al.
Published: (2021-12-01)

Liraglutide Attenuates Glucolipotoxicity-Induced RSC96 Schwann Cells’ Inflammation and Dysfunction
by: Edy Kornelius, et al.
Published: (2022-09-01)

Liraglutide exhibits anti-inflammatory activity through the activation of the PKA/CREB pathway
by: Li Wang, et al.
Published: (2019-10-01)

Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
by: Mihaela-Simona Popoviciu, et al.
Published: (2023-06-01)

Liraglutide abrogates nephrotoxic effects of chemotherapies
by: Cong Xu, et al.
Published: (2023-03-01)

Liraglutide overdose: A case report and an updated review
by: Sharafaldeen Bin Nafisah, et al.
Published: (2020-01-01)

A diabetic patient increased premature ventricular contractions after using liraglutide: a case report
by: Lilan Huang, et al.
Published: (2024-01-01)

Tissue-Based Proteomic Profiling in Patients with Hyperplasia and Endometrial Cancer
by: Khalid Akkour, et al.
Published: (2022-07-01)